- Home
- IMVT
IMVT
Immunovant Inc.
as 12-17-2024 4:00pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.2B | IPO Year: | N/A |
| Target Price: | $48.10 | AVG Volume (30 days): | 799.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.61 - $45.58 | Next Earning Date: | 02-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hughes Douglas J. | IMVT | Director | Dec 2 '24 | Sell | $28.54 | 5,425 | $154,829.50 | 119,585 | |
| Macias William L. | IMVT | Chief Medical Officer | Nov 20 '24 | Sell | $25.45 | 3,353 | $85,333.85 | 361,791 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Nov 20 '24 | Sell | $25.45 | 4,174 | $106,228.30 | 331,169 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Nov 20 '24 | Sell | $25.45 | 3,650 | $92,892.50 | 319,228 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Nov 20 '24 | Sell | $25.45 | 16,692 | $424,811.40 | 978,097 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Oct 23 '24 | Sell | $29.53 | 4,361 | $128,780.33 | 319,228 | |
| Geffner Michael | IMVT | Chief Medical Officer | Oct 23 '24 | Sell | $29.53 | 3,189 | $94,171.17 | 134,971 | |
| Stout Jay S | IMVT | Chief Technology Officer | Oct 23 '24 | Sell | $29.53 | 2,740 | $80,912.20 | 142,186 | |
| Macias William L. | IMVT | Chief Medical Officer | Oct 16 '24 | Sell | $28.79 | 3,188 | $91,782.52 | 361,791 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Oct 16 '24 | Sell | $28.79 | 3,271 | $94,172.09 | 331,169 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?
Thomson Reuters StreetEvents
a month ago
Q2 2024 Roivant Sciences Ltd Earnings Call
Zacks
a month ago
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
MT Newswires
a month ago
Immunovant Fiscal Q2 Net Loss Widens
GlobeNewswire
a month ago
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
GlobeNewswire
2 months ago
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
MT Newswires
2 months ago
Immunovant Insider Sold Shares Worth $261,845, According to a Recent SEC Filing
MT Newswires
2 months ago
Oppenheimer Adjusts Immunovant Price Target to $53 From $47, Maintains Outperform Rating
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.